Santen, Inc. — the U.S. subsidiary of specialty ophthalmology company Santen Pharmaceutical Co., Ltd. — and artificial intelligence-driven biopharmaceutical company twoXAR, Inc. have entered into a strategic research collaboration focused on the identification of new drug candidates for glaucoma.
Under the agreement, twoXAR will reportedly use its proprietary computational drug discovery platform to discover, screen, and prioritize novel drug candidates with potential application in ocular indications, with a specific focus on glaucoma. Santen will reportedly have the exclusive right to develop and commercialize drug candidates arising from the collaboration.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.